Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Millennium Pharmaceuticals Inc. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 3 distinct art units, indicating a moderately decentralized prosecution landscape. This spread suggests that the company's pharmaceutical research is being evaluated by multiple specialized groups within the USPTO.
MAHER M HADDAD is identified as the busiest examiner for the company, currently managing 2 pending office actions. These 2 busiest examiner pending actions represent a portion of the total 5 pending office actions in the portfolio. With 4 distinct examiners and 3 distinct art units involved, the company must coordinate its prosecution strategy across different examination styles. The concentration of 5 pending actions within only 3 distinct art units suggests some overlap in the technical fields being pursued, even as the workload is shared among 4 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16084383 | METHOD OF PREVENTING GRAFT VERSUS HOST DISEASE | ALDARONDO, DASIA ALI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18731923 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | WHITE, DAWANNA SHAR-DAY | 98d overdue |
| 18656201 | ANTI-CD19 ANTIBODIES AND USES THEROF | BRISTOL, LYNN ANNE | — |
| 18344724 | METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1641 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18731923 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Final Rejection | 98d overdue | Pending | Jun 03, 2024 |
| 18656201 | ANTI-CD19 ANTIBODIES AND USES THEROF | BRISTOL, LYNN ANNE | — | §112 | Non-Final OA | — | Pending | May 06, 2024 |
| 18344724 | METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS | HADDAD, MAHER M | 1641 | §102§103DP | Non-Final OA | — | Pending | Jun 29, 2023 |
| 16084383 | METHOD OF PREVENTING GRAFT VERSUS HOST DISEASE | ALDARONDO, DASIA ALI | 1600 | §103DP | Final Rejection | — | Pending | Sep 12, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMillennium Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Dawanna Shar-Day White has the most, with 1 of Millennium Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
